Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precision Biosciences Inc

5.74
+0.10001.77%
Volume:114.75K
Turnover:654.42K
Market Cap:60.17M
PE:5.52
High:5.85
Open:5.69
Low:5.50
Close:5.64
Loading ...

Precision BioSciences Inc - Cash Runway Expected to Last Into Second Half of 2026

THOMSON REUTERS
·
26 Mar

Precision BioSciences, Inc. Q4 Basic EPS USD -2.22

THOMSON REUTERS
·
26 Mar

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Business Wire
·
26 Mar

Precision BioSciences Inc expected to post a loss of $1.96 a share - Earnings Preview

Reuters
·
24 Mar

Precision BioSciences Inc expected to post a loss of $1.96 a share - Earnings Preview

Reuters
·
21 Mar

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

THOMSON REUTERS
·
21 Mar

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Business Wire
·
21 Mar

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Business Wire
·
20 Mar

Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar

Precision BioSciences presents preclinical data from PBGENE-DMD program

TIPRANKS
·
19 Mar

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Business Wire
·
19 Mar

Precision Says its Investigational New Drug Application for Hepatitis B Treatment Gets US FDA's Clearance

MT Newswires Live
·
17 Mar

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class Pbgene-Hbv Designed to Eliminate Root Cause of Chronic Hepatitis B

THOMSON REUTERS
·
17 Mar

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Business Wire
·
17 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

THOMSON REUTERS
·
24 Feb

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Business Wire
·
24 Feb

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Benzinga
·
20 Feb

Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Feb

BRIEF-Precision Biosciences Announces Initial Safety And Antiviral Activity Of Pbgene-Hbv

Reuters
·
19 Feb